Provided by Tiger Trade Technology Pte. Ltd.

Splash Beverage Group Inc.

0.4715
+0.046510.94%
Post-market: 0.4201-0.0514-10.90%19:59 EDT
Volume:1.62M
Turnover:750.33K
Market Cap:2.97M
PE:-0.01
High:0.4744
Open:0.4408
Low:0.4403
Close:0.4250
52wk High:13.40
52wk Low:0.2500
Shares:6.30M
Float Shares:6.30M
Volume Ratio:2.35
T/O Rate:25.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-34.9121
EPS(LYR):-70.9984
ROE:-1130.20%
ROA:-77.00%
PB:-0.19
PE(LYR):-0.01

Loading ...

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

THOMSON REUTERS
·
Jul 14

Splash Beverage Group - Expects $2.75 Mln Gain from Extinguishment of Indebtedness

THOMSON REUTERS
·
Jul 14

Splash Beverage Group - Settles $3.3 Mln Liabilities for $550,000 Cash

THOMSON REUTERS
·
Jul 14

Splash Beverage Group to Repay Decathlon Alpha IV Loan for $301,800.55 Under Settlement Deal

Reuters
·
Jul 14

Splash Beverage Group Issues 9,232,047 Shares in Unregistered Sale, Raises $1.27 Million

Reuters
·
Jul 11

NYSE American Accepts Splash Beverage Compliance Plan, Sets Jan. 29, 2027 Deadline to Regain Listing Standards

Reuters
·
Jul 09

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

THOMSON REUTERS
·
Jul 09

Top Premarket Decliners

MT Newswires Live
·
Jul 07

Argent Biopharma Ltd - to Receive a 15% Net Revenue Royalty on Future Sbev Global Cannepil Revenues

THOMSON REUTERS
·
Jul 07

Argent Biopharma - Enters a Global Licensing Transaction for Cannepil with Splash Beverage Group Inc

THOMSON REUTERS
·
Jul 07

Argent Biopharma - Transaction Includes $5.5 Mln Upfront Consideration for Global Licensing Rights

THOMSON REUTERS
·
Jul 07

Splash Beverage Group Secures Exclusive Worldwide License to Argent Biopharma’s Cannepil Epilepsy Drug

Reuters
·
Jul 07

Splash Beverage Acquires Exclusive Global Rights for Epilepsy Therapy CannEpil

MT Newswires Live
·
Jul 06

Mercer Street Fund Forgives USD 5 Million Argent Biopharma Debt in Cannepil Licensing Deal with Splash Beverage Group

Reuters
·
Jul 06

Splash Beverage Group - Argent Biopharma to Receive 15% Royalty on Worldwide Cannepil Sales

THOMSON REUTERS
·
Jul 06

Splash Beverage Group Acquires Exclusive Global Rights to Cannepil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential

THOMSON REUTERS
·
Jul 06

Splash Beverage Group - Buys Exclusive Worldwide Rights to Develop and Sell Cannepil

THOMSON REUTERS
·
Jul 06

Splash Beverage Group - Issues $5.5 Mln Preferred Equity; $5 Mln Argent Biopharma Debt Forgiven as License Consideration

THOMSON REUTERS
·
Jul 06

Splash Beverage Group - Secures $1 Mln Strategic Investment from C/M Capital Partners for Cannepil Development

THOMSON REUTERS
·
Jul 06

Splash Beverage Sells 767,953 Shares in Private Placement for Gross Proceeds of $117,036

Reuters
·
Jun 27